Can Agenus turn botensilimab and balstilimab into a serious post-ICI liver cancer contender?
Post-ICI liver cancer has few strong options. Agenus’ BOT plus BAL data raise the next question: can durability survive larger trials?
How AIM ImmunoTech Inc. is positioning Ampligen to overcome checkpoint inhibitor resistance in ovarian cancer
Can AIM ImmunoTech Inc.’s Ampligen improve checkpoint inhibitor responses in ovarian cancer? Explore the Phase 2 findings and implications.
Is botensilimab finally ready for a bigger melanoma spotlight? Agenus bets on ASCO 2026
Agenus will unveil first Phase 2 botensilimab melanoma data at ASCO 2026. Read why the update could reshape sentiment around its checkpoint platform.
How Agilent’s PD-L1 companion diagnostic now shapes pembrolizumab access in esophageal carcinoma
FDA approves Agilent’s PD-L1 IHC 22C3 pharmDx for esophageal and GEJ carcinoma, marking the eighth companion diagnostic indication alongside pembrolizumab. Read the analysis.
Junshi Biosciences pushes subcutaneous PD-1 therapy as China’s oncology system strains
NMPA reviews subcutaneous toripalimab across 12 cancers. Discover how the delivery shift could reshape China’s immunotherapy infrastructure.
How Brazil’s GMP approval for pembrolizumab biosimilar changes global biosimilar dynamics
Blau Farmacêutica’s pembrolizumab biosimilar earns ANVISA GMP approval—see what this means for Brazil’s global position in cancer immunotherapy.
Saudi FDA approves ImmunityBio’s ANKTIVA in NSCLC: What this means for immunotherapy 2.0
Find out how ImmunityBio’s subcutaneous immunotherapy ANKTIVA secured Saudi approval for NSCLC and what it means for global immuno-oncology.
How Agenus is taking aim at cold tumors with Fc-enhanced anti-CTLA-4 therapy
Agenus sees 23% response rate in platinum-refractory ovarian cancer with BOT+BAL. Find out how this IO combo could reshape the treatment landscape.
Can nivolumab plus AVD become the new frontline treatment in classical Hodgkin lymphoma?
FDA fast-tracks review of Opdivo plus AVD for first-line Hodgkin lymphoma. Find out what this immunotherapy combo could change for patients and providers.
Can next-gen immunotherapy combos finally crack the code in metastatic breast cancer?
The landscape of metastatic breast cancer treatment is facing a fundamental rethink, with the oncology field laser-focused on one of its greatest clinical challenges: how to break immune resistance and stop metastatic spread. Despite a wave of checkpoint inhibitor approvals and initial enthusiasm, progress in metastatic breast cancer—especially for subtypes like triple-negative and HER2-positive disease—has […]